Autoimmune diseases (AIDs) are chronic disorders characterized by inflammatory reactions against self-antigens that can be either systemic or organ specific. AIDs can differ in their epidemiologic features and clinical presentations, yet all share a remarkable complexity. AIDs result from an interplay of genetic and epigenetic factors with environmental components that are associated with imbalances in the immune system. Many of the pathogenic mechanisms of AIDs are also implicated in myasthenia gravis (MG), an AID in which inflammation of the thymus leads to a neuromuscular disorder. Our goal here is to highlight the similarities and differences between MG and other AIDs by reviewing the common transcriptome signatures and the development of germinal centers and by discussing some unresolved questions about autoimmune mechanisms. This review will propose hypotheses to explain the origin of regulatory T (T reg ) cell defects and the causes of chronicity and specificity of AIDs.
Introduction
Autoimmune diseases (AIDs) encompass more than 80 distinct chronic disorders characterized by inflammatory reactions that can either be systemic or organ specific. Despite decades of research on AIDs and improvement of therapeutic approaches, their exact etiologies remain a conundrum. However, most recent findings suggest that AIDs result from the complex interplay of various factors (genetic, epigenetic, and external factors, as well as internal components under the influence of environmental factors). While these factors are not sufficient to induce AIDs when taken individually, their temporal combinations may pave the winding road to autoimmunity.
There are many similarities between the different AIDs, and polyautoimmunity is common in patients with AIDs and their families. 1 In all cases, the disease development is the consequence of the effects of environmental factors in predisposed individuals. Predisposing factors could be genetic or nongenetic. Various predisposing genes are shared between several AIDs, suggesting a partial redundancy among these different diseases. Most of the genes identified by genome-wide association studies (GWAS) on AIDs are related to immunity. However, functional immune parameters that are commonly dysregulated in AIDs do not necessarily stem from these genetic variants, as some of them may be directly induced by nongenetic (environmental) triggering events. This was notably illustrated in reports on monozygotic (MZ) discordant twins, 2 showing that predisposing genes are not sufficient to develop an AID and that environmental factors are needed. Environmental cues include predisposing factors (low vitamin D, smoking, pollution, and sexual hormones) and triggering factors (specific drugs). signatures, the development of germinal centers (GCs), and the overexpression of B-cell activating factor (BAFF). We will also discuss some unsolved questions about autoimmune mechanisms, such as the origin of regulatory T (T reg ) cell defects. Indeed, although defects of the immune system have been well characterized, whether they pre-exist in patients before the onset of the disease or are induced by triggering events deserves to be discussed. We also propose hypotheses to explain why AIDs are chronic and how the specificity of an AID is determined.
Typical molecular signatures in MG and other AIDs
At the molecular scale, transcriptomics has largely contributed to identifying pathogenic signatures in human autoimmunity. In early-onset myasthenia gravis (EOMG), the transcriptome of thymuses, which is the inflammatory organ in this disease, was compared with sex-and aged-matched non-MG thymuses. 3, 4 Briefly, the gene hit lists were established as reported 3 and submitted to DAVID Bioinformatics. 5 Similarities were found in the Genetic Association Database that contains genetic association data from complex disorders. This analysis, shown in Table 1 , involves several AIDs, such as systemic lupus erythematosus (SLE), Sjogren's syndrome, thyroiditis, and multiple sclerosis. 4 It is noteworthy that these similarities exist despite differences in the immunological mechanisms involved in these diseases. 6 A similar analysis of the transcriptome of purified thymic T reg and conventional T (T conv ) cells from MG patients in comparison with control cells reveals a 10-fold upregulation of genes known to be involved in other AIDs, such as type 1 diabetes and autoimmune thyroiditis, and in pathological states associated with increased immune activation and inflammation, such as allograft rejection and graftversus-host disease. 7 These data suggest that T cells contribute to the similarities between MG and the other AIDs.
The genes involved in the 10 AIDs listed in Table  1 were analyzed to detect the genes shared among these disorders. We identified 16 genes dysregulated in the thymus of EOMG patients as well as in at least three other different AIDs (Table  2) . These include the genes for many proteins related to the immune response: HLA-DR and DQ, CD14 (monocytes), CD19 (B cells), CD80 (a costimulatory molecule), IL-1␤ (a cytokine), and CCL-5/RANTES (a chemokine), but also a protein involved in oxidative stress (NOS) and the protein tyrosine phosphatase, nonreceptor type 22 (PTPN22). These genes are expressed in cells other than T cells, suggesting that not only T cells but also other immune cell types are involved in MG. Most of these genes have a genetic association with MG. 8 The discovery that the level of expression of these genes is dysregulated in MG thymus suggests the presence of genetic regulators of transcription. Indeed, the combined analysis of transcriptomes and whole genomes showed that the expression level of some genes could be regulated by DNA sequence variants localized to distinct genomic regions. These variants, named expression quantitative trait loci (eQTL), provide a functional relevance for the association between genetic variants and AIDs. The eQTL analysis was recently applied to rheumatoid arthritis (RA) and successfully predicted the importance of the tumor necrosis factor (TNF) pathway in CD4 + T cells. 9 Although eQTLs have never been studied directly for MG, a screen of cis-eQTLs for 353 AID risk variants in 42 human thymic tissues identified eight eQTLs associated with seven genetic regions, including two regions that were thymus specific. 10 Overall, rather than performing even larger GWAS, understanding complex traits, such as human diseases, may require meticulous analysis or cell-specific gene networks and take into account not only core genes but also seemingly irrelevant genes that may overall have an impact on the disease.
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Among the genes highly associated with AIDs, the most striking are those encoding HLA-DR1 and PTPN22. We discuss here the potential role of PTPN22, as its gene is genetically linked to more than 20 AIDs, 12 including MG. 13 PTPN22 is a potent inhibitor of the T cell receptor signaling pathway.
14 In PTPN22 gene knockout (KO) mice, effector-memory T cells cause lymphadenopathy, splenomegaly, and more GCs. High serum concentrations of antibodies are also found in these mice. 15 In humans, a single base change in the coding region of this gene (C1858T) is observed at a high frequency in patients with AIDs. 16 Consequently, the AID incidence is 2.5-fold higher in carriers of the C1858T mutation compared with individuals without the mutation. This mutation is associated with a decrease in TCR and BCR signaling. 17 The expression of PTPN22 was found to be reduced in the MG thymus compared with controls, but the sequence of the PTPN22 gene was not investigated in these samples. Akin to the data observed in PTPN22 gene KO mice, 18 the decreased expression of PTPN22 in the thymus of MG patients could be related to the increased B cell number and GCs.
Ectopic germinal centers and autoimmunity
In physiological conditions, B cell activation and differentiation into antibody (Ab)-producing cells takes place in secondary lymphoid organs where activated B cells initiate a GC reaction and undergo the processes of somatic hypermutation and classswitch recombination of the immunoglobulin genes. Follicular B cells require T cell help and are the primary source of long-lived plasma cells and memory B cells. 19 GCs generally develop ectopically in the target organ in antibody-mediated AIDs. 20 MG is an exception, as the development of GCs is in the thymus and not in the muscle, which is the target organ (Table 3) . GCs are found in many AIDs, such as Sjogren's syndrome, RA, Hashimoto's thyroiditis, SLE, multiple sclerosis, and primary biliary cirrhosis, as well as dermatomyositis and polymyositis (reviewed in Ref. 6) . Surprisingly, the development of GCs in the thymus of MG patients is not a general MG feature, as it occurs mainly in young female patients with anti-AChR antibodies 21 but not in patients with anti-muscle-specific kinase antibodies. 22 The reason for this difference is still poorly understood.
The generation of GCs is very similar in all AIDs, as it is associated with chemokine overproduction (CXCL13, CCL21, CCL19, and CXCL12) 23 and active angiogenesis involving high endothelial venules (HEVs) and lymphatic vessels. 24, 25 In the MG thymus, the HEVs likely contribute to the recruitment of B cells and antigen-presenting cells, as these cells can be detected close to the HEVs. 26 The production of auto-antibodies resulting from GC development usually precedes the disease. 27 In MG thymuses, B cells appear to derive from an antigendriven reaction. 28 These thymic B cells can produce antibodies to AChR, as assessed by titration in culture supernatants of thymic cells 29 or in the sera of immunodeficient mice grafted with MG thymic tissue. 30, 31 Importantly, anti-AChR antibodies produced by MG thymic B cells are pathogenic, since grafts of MG thymic fragments could result in myasthenic symptoms in immunodeficient mice. 32 The increased number of B cells in the MG thymus is associated with increased expression of BAFF, a factor supporting survival and differentiation of B cells. 33 Increased serum levels of BAFF are found in MG as well as in several other AIDs. 34 Overexpression of BAFF in mice results in increased B cell numbers in the spleen and lymph nodes and an SLElike autoimmune phenotype. 35 Inhibition of BAFF reduces the severity of the ongoing disease, supporting its pathogenic role. 36 In humans, an anti-BAFF monoclonal antibody (belimumab) has proven to be efficient in SLE and RA and is approved for the treatment of SLE. 21 In MG, a phase II clinical trial using this monoclonal antibody is ongoing (ClinicalTrials. gov: NCT01480596).
Altogether, the development of GCs and the overexpression of BAFF are hallmarks of AIDs. The efficiency of anti-BAFF therapy in animal models and patients suggests a pathogenic role of BAFF in AIDs. Additionally, the presence of GCs in the pathogenic organs highlights its pivotal role in the recruitment of inflammatory cells and initiation and propagation of the disease. Note: Many AIDs display ectopic GCs in their target organs, while in MG the ectopic GCs are found in the thymus and not in the target organ, the muscle.
Origin of the defect of T reg cells
T reg cells are of paramount importance to prevent excessive inflammation in various organs. The lack of functional T reg cells in genetic diseases, including scurfy mice and humans with IPEX syndrome, leads to a broad range of inflammatory disorders affecting various tissues. 37 As such, T reg cell defects have been considered a primary cause of AIDs. However, one could ask whether the T reg cell dysfunction exists before the onset of the disease or is provoked by the inflammatory event induced by the triggering components. The defect of T reg cells generally coexists with the inflammatory processes, suggesting several hypotheses: (1) the inflammation might develop because of a poor regulation of the immune system, (2) the T reg cells could become inefficient because of the inflammatory environment, or (3) a common factor concomitantly leads to both effects.
According to the literature, several experimental findings support the hypothesis that T reg cell defects in AIDs could be a consequence and not necessarily a primary cause of the disease. We summarize these arguments here.
First, a defect in T reg function can appear after immunization with an autoantigen in experimental autoimmunity. For example, in the EAMG rat model, the induction of the disease by immunization with Torpedo AChR results in a decreased frequency and suppressive activity of T reg cells in the spleen and peripheral blood compared with control rats. 38 Second, the fact that the T reg cell defect is often concomitant with a resistance of T conv cells to suppression by normal T reg cells 39 suggests that the immune imbalance affects not only the T reg cells, but more likely the whole immune system. The resistance of T conv cells is likely due to the inflammatory microenvironment 40 and could be mediated by TNF-␣. In MG cells, blocking TNF-␣ decreases the resistance of thymic T conv cells to suppression, 7 supporting the hypothesis that inflammatory molecules are at least partially responsible for the resistance of T conv cells to suppression. In RA, T cells become resistant to regulation at the site of inflammation, and this contributes to the altered immune balance in the inflamed joints of RA patients. 41 Third, defects of T reg cells do not appear to be intrinsic, as they can be reversed in vitro or in vivo. Anti-inflammatory drugs, such as dexamethasone, were shown to restore the function of T reg cells. 42 Other immunosuppressive drugs, such as rapamycin, can have a marked effect on T reg cell number and function (reviewed in Ref. 43 ). In many cases, as soon as AID patients are treated with antiinflammatory drugs, T reg cell function is improved. The commonly used corticosteroid drug improves T reg cell function in SLE, 44 MG, 45 and RA 46 patients. Intravenous immunoglobulins that are commonly administrated in patients with AIDs appear to act at least partially by restoring T reg cell function and number. 47 In MG animal models, T reg cell number and function are restored by therapeutic drugs. In mice, one example is therapy with a peptide inhibitor of the plasminogen activator system in tissue plasminogen activator null (Tpa -/-) mice that have severe MG and defects in T reg cell numbers. 48 Following the injection of the peptide inhibitor, the disease severity is reduced, and T reg cell numbers are increased. A second example is therapy via intravenous immunoglobulins or a subfraction including recombinant polyvalent IgG2a Fc (M045) in the classical model of EAMG induced by immunization with Torpedo AChR. M045 treatment improves the course of the disease and causes an expansion of the FOXP3 + T reg cell population. 49 Together, these data suggest that T reg cell defects in acquired AIDs are not necessarily pre-existing to the triggering event. Since the experimental triggering events (e.g., immunization) in vivo are different from the ones in natura, one major challenge will be to understand how predisposing factors (genetics, vitamin D level, hormones, microbiota, etc.) could contribute to the T reg cell defects in AIDs.
How to explain the specificity of autoimmune diseases
Although frequent polyautoimmunity is observed in families affected by AIDs, most often the patients have only one specific disease. Once the immune system is overactivated, one could ask why a patient will develop a particular disease and not another one. Several nonmutually exclusive hypotheses could be proposed.
First, the role of HLA genes has long been suspected. Each HLA molecule has a certain affinity for antigen-derived peptides. For instance, a peptide from an autoantigen will fit into the peptide-binding pocket of a particular HLA-DR allelic variant, and the HLA-peptide complex will be recognized by the T cell receptor, while other HLA-DR molecules would not bind the same autoantigenic peptide with high affinity. However, this hypothesis does not explain why a certain HLA haplotype (e.g., HLA-DR3) is the susceptibility locus for several AIDs, including SLE, type 1 diabetes, autoimmune thyroiditis, Sjogren's syndrome, and MG. One hypothesis could be that HLA-DR3 is more permissive than other HLA molecules to the presentation of in situ-generated hybrid molecules containing self-peptides, a phenomenon that was recently described for diabetes. 50 Second, the nature of the triggering event could contribute to the specificity of the disease. Toll-like receptors (TLRs) are involved in the recognition by the innate immune system of a broad range of microbial ligands that can induce a disease in several experimental models of autoimmunity, including RA, diabetes, and atherosclerosis (reviewed in Ref. 51) . It is worth mentioning that some TLRs are more specifically associated with some AIDs. For example, TLR2 or TLR4 polymorphisms are frequently associated with RA, while TLR5 and TLR8 polymorphisms are associated with SLE and Sjogren's syndrome (reviewed in Ref. 51 ). Alternatively, regardless of TLR polymorphisms, qualitative environmental variations of TLR ligands may contribute to AIDs. For example, type 1 diabetes is associated with a specific lipopolysaccharide, the microbial TLR4 ligand. 52 In MG, we have shown that the TLR3 agonist poly(I:C), but no other TLR agonists, can upregulate the expression of ␣-AChR in thymic cells and induce myasthenic symptoms when injected into mice. 53 Interestingly, poly(I:C) does not affect the expression of other autoantigens, suggesting that poly(I:C) has a specific effect on AChR.
Third, the nature of the organ affected by the triggering molecule is likely essential for the specificity of the autoimmune reaction. Infections can occur in any organ, but taking into account the cellular and molecular specificities of each organ, the functional consequences of a given perturbation could be very different. This assumption is particularly relevant in the perspective of the eQTLs that are genetic variants associated with the transcriptional expression of one or several genes. Indeed, more than 10% of eQTLs can be context specific, being selectively active in specific tissues or cell types. 54 A recent study found that about half of eQTLs are tissue specific, 55 highlighting the importance of considering tissues or cells of interest to understand how eQTLs may influence AIDs. Thus, a triggering event occurring in an organ that permits the excessive transcriptional expression of genes involved in the immune response could explain the targeting of this specific organ.
Why are AIDs chronic?
While AIDs are generally incurable chronic diseases, transient autoimmunity can also be swiftly induced by environmental triggers (notably drugs) and disappear upon their withdrawal. This fact indicates that chronicity is not a necessary consequence of autoimmunity. Many drugs can induce the production of antibodies and autoimmune symptoms, although the presence of autoantibodies is much more frequent than the appearance of symptoms (reviewed in Ref. 56 ).
In the case of SLE, a very common AID, a drug-induced disease was first described in 1945 after the treatment with sulfadiazine. Since then, a large number of drugs (more than 100) have been implicated in inducing lupus. Drug-induced SLE accounts for about 10% of all SLE cases, and its presentation is similar to idiopathic SLE, but the symptoms usually resolve within weeks after drug withdrawal. 57 Thus, AIDs are not inevitably chronic. In drug-induced diseases, it is possible that the pathogenic effects are minimal, as the disease is at an early stage. If this hypothesis is exact, an early diagnostic will provide a better chance of reversing the disease.
While the findings exposed above indicate that chronicity is not an inevitable consequence of autoimmunity, it is likely that autoimmunity results from a chronic imbalance involving both environmental and intrinsic factors. Several nonmutually exclusive hypotheses could explain the chronicity of the autoimmune response.
First, an ongoing antigenic availability linked to the maintenance of the GCs could account for the chronicity of the production of the autoantibodies. In physiological conditions, GC reactions disappear a few weeks after their induction, while in AIDs these structures are very stable. For example, in AChR-MG patients, GCs could be found in the thymus of MG patients even 10 years or more after disease onset, suggesting that B cells migrate continuously to the thymus. 4 Since the autoantigen (AChR) is expressed in several thymic cell types 58, 59 and could be upregulated by interferons, 33 high expression of the autoantigen will promote its availability. The stability of the GCs could be due to a defective mechanism of apoptosis within the GC. Indeed, the resolution phase of GCs is associated with high levels of apoptosis. 60 While the antiapoptotic factor Bcl-2 is not expressed in GCs of control tonsils, it is expressed in thymic GCs of MG patients, where it may prevent cell apoptosis. 61 Second, the resolution of inflammation, which is a complex coordinated process to return to tissue homeostasis, could be defective. Resolution of inflammation appears to be a bridge between innate and adaptive immunity. An incomplete resolution of the initial acute response that does not engage a proper adaptive immune response could lead to chronic inflammation. 62 The inflammation resolution process is controlled by a variety of endogenous mediators that include specialized proresolving mediators, such as lipoxins and resolvins, protein/peptide mediators, gases, and nucleotides. 63 As a proof of concept in the murine model of autoimmune arthritis, the resolution of inflammation that is disrupted by cyclooxygenase-2 inhibition is restored by prostaglandin E2-mediated lipoxin A4 production. 64 In another model of murine inflammatory arthritis, antiarthritic properties of resolvin D1 could be demonstrated. 65 In MG, in a recent analysis of the transcriptome and methylome of peripheral monocytes in MZ twins discordant and concordant for MG, we showed a decreased expression of several transcripts associated with immune homeostasis and inflammation resolution. Thus, the impaired monocyte function in MG and the decreased expression of genes associated with inflammation resolution could contribute to the chronicity of the disease. These examples show that the resolution of inflammation could be less efficient in AID patients than in other individuals, raising the susceptibility of developing a chronic disease.
Third, immune checkpoints are major cell surface inhibitory receptors that may also be involved in the chronicity of AIDs. Intracellular checkpoints limit the activation of inflammatory cells. 66 Thus, reduced expression of these molecules could prevent an efficient regulation of the immune cell activation. PD-1 single-nucleotide polymorphisms (SNPs) have been associated with several AIDs, including SLE and RA. 67 However, it is known that SNPs only rarely fully explain a phenotype and that other genetic variants should be concomitantly taken into account. This is illustrated by PD-1 deficiency in mice, which results in the development of a lupus-like AID or a cardiomyopathy depending on the genetic background. 68, 69 Immune checkpoint blockers (ICBs) have recently demonstrated remarkable efficiency against melanoma and nonsmall cell lung carcinoma, but they can induce immune-related adverse events. In addition to rashes, hepatitis, or colitis, ICBs have been associated with the development or exacerbation of MG in 22 cases. 70 This observation is all the more striking, as the CTLA-4 gene is strongly associated with MG. 71 Interestingly, while anti-CTLA-4 treatments have been linked to the development of MG in some cases, humans bearing mutations in the CTLA-4 gene develop a spectrum of autoimmune syndromes distinct from MG. 72, 73 Overall, this may be sufficient to precipitate autoimmunity in a predisposing background.
Fourth, as discussed above, T reg cell defects could be induced by the high level of inflammation.
However, in a highly inflammatory environment, conventional T cells might be out of control and resistant to suppression. If the T reg cells are unable to reduce the proliferation of T conv cells, this will predictably result in a chronic pathological process.
Inflammation can also lead to a reprogramming of T reg cells into proinflammatory T H 17 cells (ex-T reg cells), illustrating a vicious circle whereby inflammation (which can be induced by T H 17 cells) leads to more inflammation. The pathogenic role of ex-T reg cells has been demonstrated in various experimental autoimmune models, including RA. 74 Conversely, resolution of inflammation is associated with the transdifferentiation of T H 17 cells into T reg cells. 75 However, since the defective T reg cells are unable to reduce the inflammation level, the autoimmune response is maintained at a high level, contributing to the chronicity of the disease.
Conclusions
AIDs are typically complex diseases constituting major intellectual challenges for clinicians and biologists. The most advanced methods of genetic screening or immune screening seemed to be promising but have not thus far enabled full understanding of the causes of AIDs. However, it is of utmost importance that we now better apprehend the extent to which AIDs could be complex. Genetically, it is now clear that polygenic explanations did not fulfill expectations and that more efforts are needed to understand how the interplay of environmental clues may have a phenotypic impact. Immunologically, it is of utmost importance to distinguish co-occurring dysregulations from potentially causative perturbations that may even have returned to normal states. Collectively, AIDs remain challenging to study, and interdisciplinary approaches will be more than ever essential to unravel the complexity and provide better and more personalized therapeutic approaches in the future.
